Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.

The objective of this study was to estimate the net cost of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) compared to ATRA plus chemotherapy when used in first-line acute promyelocytic leukemia (APL) treatment for low to intermediate risk patients from the perspective of the overall...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Morgan Kruse, Rebecca Wildner, Gisoo Barnes, Monique Martin, Udo Mueller, Francesco Lo-Coco, Ashutosh Pathak
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science (PLoS) 2015-01-01
Серии:PLoS ONE
Online-ссылка:http://europepmc.org/articles/PMC4534409?pdf=render
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы